PharmTox GLP offers a comprehensive suite of preclinical research services that support the development and evaluation of novel therapeutics across multiple scientific domains. Our capabilities span functional genomics, pharmacological screening, toxicological profiling, and delivery system formulation – providing critical experimental data to advance drug discovery and regulatory submission.
Pharmacology and Toxicology Testing: IC50 for Tumor Cell Lines
Accurate quantification of drug potency is central to oncology drug development. Our IC50 testing services involve concentration-dependent cytotoxicity assays that determine the half-maximal inhibitory concentration (IC50) of small molecules, nucleic acids, and biologics in a wide range of tumor-derived cell lines. These in vitro pharmacology studies provide insight into compound efficacy, resistance mechanisms, and dose-response behavior essential for prioritizing lead candidates.
Xenograft Animal Service: Immunocompromised NOD/SCID Mice
Our in vivo oncology studies utilize immunodeficient NOD/SCID mice for human tumor xenograft modeling. These models permit the engraftment of human cancer cells without immune rejection, enabling the evaluation of tumor progression, metastasis, and therapeutic response in a physiologically relevant setting. Endpoint analysis includes tumor volume monitoring, histopathology, and molecular readouts to support efficacy claims and biomarker validation.
Therapeutic RNAi Development: Targeted siRNA, qPCR Assays
We design and validate targeted RNA interference strategies using custom siRNA constructs for gene silencing in both in vitro and in vivo systems. Our workflow includes rational siRNA design, sequence-specific qPCR validation, and assessment of downstream protein-level effects. These services facilitate functional studies of gene targets, validation of therapeutic pathways, and development of precision RNAi-based interventions.
Liposome Encapsulation Services: siRNA, miRNA, DNA, Proteins
We offer advanced liposome formulation services for encapsulating a range of biomolecules, including double-stranded RNA, plasmid DNA, and therapeutic proteins. Our custom liposome systems are engineered for enhanced bioavailability, stability, and tissue targeting. These delivery vehicles are suitable for in vitro screening, systemic administration, and organ-specific applications in small animal models.
ELISA and Cell-Based Assay Development (Cell Cycle, Viability)
PharmTox GLP supports high-content analysis through custom ELISA assay development and cell-based viability assays. Our platform includes multiplex cytokine quantification, growth factor response profiling, and analysis of cell proliferation, apoptosis, and metabolic activity. We tailor assay design to support studies in oncology, immunology, and toxicology, ensuring reproducible quantification of biological responses.
Apoptosis Assay: Caspase-3 and Caspase-7 Cell Line Screen
Our apoptosis assays detect early and late-stage cell death by quantifying caspase-3 and caspase-7 activation in cancer and primary cell lines. These fluorometric and luminescent-based assays provide mechanistic insight into cytotoxic effects triggered by test compounds. This data informs the classification of compounds as pro-apoptotic agents and supports mechanism-of-action studies in drug discovery programs.
RNAi Consulting: Technology Development and Evaluation
PharmTox GLP offers consulting services for organizations developing RNAi technologies, from conceptual design through experimental validation. Our team provides strategic guidance on siRNA and shRNA construct optimization, transfection methodologies, knockdown quantification, and off-target risk assessment. We support early-stage innovation as well as translational research aiming to bring RNAi therapeutics into clinical development.